518 related articles for article (PubMed ID: 33571320)
1. Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae.
Brunaugh AD; Seo H; Warnken Z; Ding L; Seo SH; Smyth HDC
PLoS One; 2021; 16(2):e0246803. PubMed ID: 33571320
[TBL] [Abstract][Full Text] [Related]
2. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
Xu J; Shi PY; Li H; Zhou J
ACS Infect Dis; 2020 May; 6(5):909-915. PubMed ID: 32125140
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration.
Seow HC; Liao Q; Lau ATY; Leung SWS; Yuan S; Lam JKW
Int J Pharm; 2022 May; 619():121704. PubMed ID: 35358643
[TBL] [Abstract][Full Text] [Related]
4. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
5. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
6. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
7. Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.
Ko M; Chang SY; Byun SY; Ianevski A; Choi I; Pham Hung d'Alexandry d'Orengiani AL; Ravlo E; Wang W; Bjørås M; Kainov DE; Shum D; Min JY; Windisch MP
Viruses; 2021 Apr; 13(4):. PubMed ID: 33918958
[TBL] [Abstract][Full Text] [Related]
8. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
Mishra J; Prasun C; Sahoo PK; Nair MS
Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
[TBL] [Abstract][Full Text] [Related]
9. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
10. Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation.
Seow HC; Cai JP; Pan HW; Luo C; Wen K; Situ J; Wang K; Cao H; Leung SWS; Yuan S; Lam JKW
J Control Release; 2023 Jun; 358():128-141. PubMed ID: 37084889
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV.
Scroggs SLP; Offerdahl DK; Flather DP; Morris CN; Kendall BL; Broeckel RM; Beare PA; Bloom ME
Viruses; 2020 Dec; 13(1):. PubMed ID: 33374514
[TBL] [Abstract][Full Text] [Related]
12. Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection.
Hobson JJ; Savage AC; Dwyer AB; Unsworth C; Massam J; Arshad U; Pertinez H; Box H; Tatham L; Rajoli RKR; Neary M; Sharp J; Valentijn A; David C; Curley P; Liptrott NJ; McDonald TO; Owen A; Rannard SP
Nanoscale; 2021 Apr; 13(13):6410-6416. PubMed ID: 33885522
[TBL] [Abstract][Full Text] [Related]
13. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
14. Autophagy-Inducing Inhalable Co-crystal Formulation of Niclosamide-Nicotinamide for Lung Cancer Therapy.
Ray E; Vaghasiya K; Sharma A; Shukla R; Khan R; Kumar A; Verma RK
AAPS PharmSciTech; 2020 Sep; 21(7):260. PubMed ID: 32944787
[TBL] [Abstract][Full Text] [Related]
15. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
[TBL] [Abstract][Full Text] [Related]
16. Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2).
Weiss A; Touret F; Baronti C; Gilles M; Hoen B; Nougairède A; de Lamballerie X; Sommer MOA
PLoS One; 2021; 16(12):e0260958. PubMed ID: 34855904
[TBL] [Abstract][Full Text] [Related]
17. Valinomycin as a potential antiviral agent against coronaviruses: A review.
Zhang D; Ma Z; Chen H; Lu Y; Chen X
Biomed J; 2020 Oct; 43(5):414-423. PubMed ID: 33012699
[TBL] [Abstract][Full Text] [Related]
18. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
19. Effect of the Phytochemical Agents against the SARS-CoV and Some of them Selected for Application to COVID-19: A Mini-Review.
Idrees M; Khan S; Memon NH; Zhang Z
Curr Pharm Biotechnol; 2021; 22(4):444-450. PubMed ID: 32619167
[TBL] [Abstract][Full Text] [Related]
20. Niclosamide inhalation powder made by thin-film freezing: Multi-dose tolerability and exposure in rats and pharmacokinetics in hamsters.
Jara MO; Warnken ZN; Sahakijpijarn S; Moon C; Maier EY; Christensen DJ; Koleng JJ; Peters JI; Hackman Maier SD; Williams Iii RO
Int J Pharm; 2021 Jun; 603():120701. PubMed ID: 33989748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
